EXOPYR Press

EXOPYR Enters TIME’s Best Inventions of 2026

St. Petersburg, FL – March 4, 2026 – Extinguish Inflammation™ a newly introduced system-level inflammation reset architecture, has been submitted for consideration in the TIME Best Inventions of 2026 awards, which recognize innovations that are changing how the world works, lives, and heals. TIME Best Inventions is TIME’s annual list of the year’s most exceptional products, services, and breakthroughs reshaping industries and improving lives.

According to Dr. Justin Mandel, DOM the founder EXOPYR, LLC, Extinguish Inflammation™ was built on a simple insight: inflammation behaves as a coordinated biological system, yet modern care has historically addressed it through isolated pathways. The EXOPYR framework reorganizes that approach by coordinating intervention across four interdependent levels of biology – systemic signaling, cellular metabolism, gene regulation, and repair capacity.

The program is structured as an eight-week reset architecture verified through standardized laboratory testing before and after intervention. Five core biomarkers including hs-CRP, fasting insulin, fasting glucose, homocysteine, and uric acid provide measurable confirmation of physiological change.

“Inflammation has never lacked treatments,” said Dr. Mandel. “What it has lacked is structural coordination. The insight behind EXOPYR is that inflammation functions as a network. When the system is addressed coherently rather than in fragments, outcomes can be measured and verified.”

Unlike conventional approaches that focus on suppressing isolated inflammatory pathways, Extinguish Inflammation sequences interventions across multiple biological levels while maintaining laboratory verification of results. The system was developed to create a governed, repeatable architecture for addressing chronic inflammation.

TIME’s Best Inventions awards highlight products, technologies, and services that demonstrate originality, efficacy, ambition, and impact. Editors evaluate submissions from around the world across industries including healthcare, technology, sustainability, and consumer innovation.

EXOPYR’s submission reflects a broader effort to introduce a new category of inflammation medicine built around coordinated system design and measurable biomarker verification.

Founder-led cohorts of the Extinguish Inflammation program are scheduled to open in the second quarter of this year in limited capacity.

More information about the system and the underlying concept that “Inflammation Is a System” can be found at www.EXOPYR.com

About EXOPYR^®

Extinguish Inflammation™ is EXOPYR’s four-level inflammation reset system designed to address inflammation as a coordinated biological network rather than isolated pathways. The architecture sequences interventions across systemic signaling, cellular metabolism, gene regulation, and repair capacity, with measurable change verified through standardized biomarker testing.

Doctor Introduces Category-Defining Inflammation Reset Built on a Simple Insight: Inflammation Is a System

St. Petersburg, FL – January 12, 2026 – After more than a century of medical advances, chronic inflammation remains one of healthcare’s most persistent and costly challenges. Aspirin, steroids, biologics, and lifestyle interventions have each delivered partial relief, yet outcomes often plateau or regress. According to Dr. Justin Mandel, DOM, the reason is not a lack of treatments, but a fundamental misunderstanding of the problem itsel

Inflammation is not a single pathway. Inflammation is a system.

Historically, inflammation has been treated in isolated pieces rather than as a coordinated, multi-level biological process. When one pathway is targeted in isolation, other levels compensate, allowing inflammation to persist.

Today, Dr. Mandel announced the launch of Extinguish Inflammation™, a category-defining inflammation reset designed around this core insight. Delivered through EXOPYR, LLC, the eight-week, lab-verified program is built to address inflammation simultaneously across four integrated levels: systemic signaling, cellular metabolism, genetic expression, and repair and recovery.

“Inflammation does not behave like a single switch you can turn off,” said Dr. Mandel. “It behaves like a system. When care is fragmented, results fragment. This reset was designed as a single coordinated process so all four levels are addressed, sequenced, and verified together.”

The Extinguish Inflammation™ reset verifies change using standardized Core-4 biomarker testing conducted before and after the program, including high-sensitivity C-reactive protein, fasting insulin, homocysteine, and uric acid. Lab conditions and timing are standardized to reduce noise and false interpretation, allowing outcomes to be confirmed in black and white.

The program is delivered through a Luxury Health Concierge execution model, created to support the level of coordination required for a true system-level reset. Concierge oversight manages lab logistics, pacing, and follow-up to reduce friction and prevent cross-interference between interventions

Key elements of the reset include:

Measured, not promised: Core-4 labs at baseline and completion with standardized draw protocols to ensure valid comparison.
Coordinated execution: Mobile phlebotomy prioritized in metropolitan and suburban regions, proactive check-ins, and clear guidance to prevent lab confounders.
Four-level sequencing: Structured nutrition phases, daily mind-body recalibration, and supporting interventions applied in deliberate order.
Privacy-first reporting: Individuals receive private outcome reviews, while employer programs are offered with de-identified, cohort-level results tied to performance indicators such as absenteeism, presenteeism, and retention.

“Inflammation has never lacked treatments,” Mandel added. “What it lacked was governance. Once you recognize that inflammation is a system, the solution has to be systemic as well. That shift changes what becomes possible.”

Founder-led cohorts are opening in limited capacity for individuals, alongside pilot programs for employers seeking lab-verified inflammation reduction without sacrificing privacy, efficiency, or discretion.

Learn more at

www.EXOPYR.com

About EXOPYR, LLC